Atherosclerosis. The Path From Genomics to Therapeutics

Journal of the American College of Cardiology

Volumn 49, Issue 15, 2007, Pages 1589-1599

  Miller, David T ^a   Ridker, Paul M ^a   Libby, Peter ^a   Kwiatkowski, David J ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE ACTIVATING PROTEIN; LEUKOTRIENE B4; MYOCYTE ENHANCER FACTOR 2;

ATHEROSCLEROSIS; CLINICAL PRACTICE; DISEASE PREDISPOSITION; GENE EXPRESSION; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC LINKAGE; GENOMICS; GENOTYPE; HEART INFARCTION; HUMAN; METABOLOMICS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEOMICS; REVIEW; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

ATHEROSCLEROSIS; CARDIAC SURGICAL PROCEDURES; CARDIOTONIC AGENTS; CORONARY ARTERIOSCLEROSIS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION TO DISEASE; GENOME, HUMAN; GENOMICS; HUMAN GENOME PROJECT; HUMANS; MALE; PROGNOSIS; PROTEOMICS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 34047273189     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2006.12.045     Document Type: Review

References (75)

1. Rosamond W.D., Chambless L.E., Folsom A.R., et al. Trends in the incidence of myocardial infarction and in mortality due to coronary heart disease, 1987 to 1994. N Engl J Med 339 (1998) 861-867
2. Wang Q. Advances in the genetic basis of coronary artery disease. Curr Atheroscler Rep 7 (2005) 235-241
3. Topol E.J. The genomic basis of myocardial infarction. J Am Coll Cardiol 46 (2005) 1456-1465
4. Watkins H., and Farrall M. Genetic susceptibility to coronary artery disease: from promise to progress. Nat Rev Genet 7 (2006) 163-173
5. Tuomisto T.T., and Yla-Herttuala S. What have we learnt about microarray analyses of atherogenesis?. Curr Opin Lipidol 16 (2005) 201-205
6. Bijnens A.P., Lutgens E., Ayoubi T., Kuiper J., Horrevoets A.J., and Daemen M.J. Genome-wide expression studies of atherosclerosis: critical issues in methodology, analysis, interpretation of transcriptomics data. Arterioscler Thromb Vasc Biol 26 (2006) 1226-1235
7. Tuomisto T.T., Binder B.R., and Yla-Herttuala S. Genetics, genomics and proteomics in atherosclerosis research. Ann Med 37 (2005) 323-332
8. Boerwinkle E., Ellsworth D.L., Hallman D.M., and Biddinger A. Genetic analysis of atherosclerosis: a research paradigm for the common chronic diseases. Hum Mol Genet 5 (1996) 1405-1410
9. Hunter D.J. Gene-environment interactions in human diseases. Nat Rev Genet 6 (2005) 287-298
10. Goldstein J.L., and Brown M.S. The LDL receptor defect in familial hypercholesterolemia. Implications for pathogenesis and therapy. Med Clin North Am 66 (1982) 335-362
11. Breslow J.L. Genetic differences in endothelial cells may determine atherosclerosis susceptibility. Circulation 102 (2000) 5-6
12. Pajukanta P., Cargill M., Viitanen L., et al. Two loci on chromosomes 2 and X for premature coronary heart disease identified in early- and late-settlement populations of Finland. Am J Hum Genet 67 (2000) 1481-1493
13. Francke S., Manraj M., Lacquemant C., et al. A genome-wide scan for coronary heart disease suggests in Indo-Mauritians a susceptibility locus on chromosome 16p13 and replicates linkage with the metabolic syndrome on 3q27. Hum Mol Genet 10 (2001) 2751-2765
14. Harrap S.B., Zammit K.S., Wong Z.Y., et al. Genome-wide linkage analysis of the acute coronary syndrome suggests a locus on chromosome 2. Arterioscler Thromb Vasc Biol 22 (2002) 874-878
15. Broeckel U., Hengstenberg C., Mayer B., et al. A comprehensive linkage analysis for myocardial infarction and its related risk factors. Nat Genet 30 (2002) 210-214
16. Wang Q., Rao S., Shen G.Q., et al. Premature myocardial infarction novel susceptibility locus on chromosome 1P34-36 identified by genomewide linkage analysis. Am J Hum Genet 74 (2004) 262-271
17. Helgadottir A., Manolescu A., Thorleifsson G., et al. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet 36 (2004) 233-239
18. Mehrabian M., Allayee H., Wong J., et al. Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis susceptibility in mice. Circ Res 91 (2002) 120-126
19. Wang X., Ria M., Kelmenson P.M., et al. Positional identification of TNFSF4, encoding OX40 ligand, as a gene that influences atherosclerosis susceptibility. Nat Genet 37 (2005) 365-372
20. Hauser E.R., Crossman D.C., Granger C.B., et al. A genomewide scan for early-onset coronary artery disease in 438 families: the GENECARD Study. Am J Hum Genet 75 (2004) 436-447
21. Ria M., Eriksson P., Boquist S., Ericsson C.G., Hamsten A., and Lagercrantz J. Human genetic evidence that OX40 is implicated in myocardial infarction. Biochem Biophys Res Commun 339 (2006) 1001-1006
22. Ridker P.M., Rifai N., Rose L., Buring J.E., and Cook N.R. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347 (2002) 1557-1565
23. Danesh J., Wheeler J.G., Hirschfield G.M., et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 350 (2004) 1387-1397
24. Carlson C.S., Aldred S.F., Lee P.K., et al. Polymorphisms within the C-reactive protein (CRP) promoter region are associated with plasma CRP levels. Am J Hum Genet 77 (2005) 64-77
25. Miller D.T., Zee R.Y.L., Suk Danik H.J., et al. Association of common CRP gene variants with CRP levels and cardiovascular events. Ann Hum Genet 69 (2005) 623-638
26. Kathiresan S., Larson M.G., Vasan R.S., et al. Contribution of clinical correlates and 13 C-reactive protein gene polymorphisms to interindividual variability in serum C-reactive protein level. Circulation 113 (2006) 1415-1423
27. Kovacs A., Green F., Hansson L.O., et al. A novel common single nucleotide polymorphism in the promoter region of the C-reactive protein gene associated with the plasma concentration of C-reactive protein. Atherosclerosis 178 (2005) 193-198
28. Casas J.P., Shah T., Cooper J., et al. Insight into the nature of the CRP-coronary event association using Mendelian randomization. Int J Epidemiol 35 (2006) 922-931
29. Shiffman D., Ellis S.G., Rowland C.M., et al. Identification of four gene variants associated with myocardial infarction. Am J Hum Genet 77 (2005) 596-605
30. Zee R.Y.L., Michaud S., Hegener H.H., Diehl K.A., and Ridker P.M. A prospective replication-study of five gene variants previously associated with risk of myocardial infarction. J Thromb Hemost 4 (2006) 2093-2095
31. Hirschhorn J.N., Lohmueller K., Byrne E., and Hirschhorn K. A comprehensive review of genetic association studies. Genet Med 4 (2002) 45-61
32. Helgadottir A., Gretarsdottir S., St. Clair D., et al. Association between the gene encoding 5-lipoxygenase-activating protein and stroke replicated in a Scottish population. Am J Hum Genet 76 (2005) 505-509
33. Lohmussaar E., Gschwendtner A., Mueller J.C., et al. ALOX5AP gene and the PDE4D gene in a Central European population of stroke patients. Stroke 36 (2005) 731-736
34. Zee R.Y., Cheng S., Hegener H.H., Erlich H.A., and Ridker P.M. Genetic variants of arachidonate 5-lipoxygenase-activating protein, and risk of incident myocardial infarction and ischemic stroke: a nested case-control approach. Stroke 37 (2006) 2007-2011
35. Helgadottir A., Manolescu A., Helgason A., et al. A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction. Nat Genet 38 (2006) 68-74
36. Tang H. Confronting ethnicity-specific disease risk. Nat Genet 38 (2006) 13-15
37. Cohen J.C., Boerwinkle E., Mosley Jr. T.H., and Hobbs H.H. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 354 (2006) 1264-1272
38. Ozaki K., Ohnishi Y., Iida A., et al. Functional SNPs in the lymphotoxin-alpha gene that are associated with susceptibility to myocardial infarction. Nat Genet 32 (2002) 650-654
39. McCarthy J.J., Parker A., Salem R., et al. Large scale association analysis for identification of genes underlying premature coronary heart disease: cumulative perspective from analysis of 111 candidate genes. J Med Genet 41 (2004) 334-341
40. Gibbons G.H., Liew C.C., Goodarzi M.O., et al. Genetic markers: progress and potential for cardiovascular disease. Circulation 109 (2004) IV47-IV58
41. Casas J.P., Cooper J., Miller G.J., Hingorani A.D., and Humphries S.E. Investigating the genetic determinants of cardiovascular disease using candidate genes and meta-analysis of association studies. Ann Hum Genet 70 (2006) 145-169
42. Herbert A., Gerry N.P., McQueen M.B., et al. A common genetic variant is associated with adult and childhood obesity. Science 312 (2006) 279-283
43. Cook S.A., and Rosenzweig A. DNA microarrays: implications for cardiovascular medicine. Circ Res 91 (2002) 559-564
44. Ma J., and Liew C.C. Gene profiling identifies secreted protein transcripts from peripheral blood cells in coronary artery disease. J Mol Cell Cardiol 35 (2003) 993-998
45. Seo D., Wang T., Dressman H., et al. Gene expression phenotypes of atherosclerosis. Arterioscler Thromb Vasc Biol 24 (2004) 1922-1927
46. Karra R., Vemullapalli S., Dong C., et al. Molecular evidence for arterial repair in atherosclerosis. Proc Natl Acad Sci U S A 102 (2005) 16789-16794
47. Tabibiazar R., Wagner R.A., Ashley E.A., et al. Signature patterns of gene expression in mouse atherosclerosis and their correlation to human coronary disease. Physiol Genomics 22 (2005) 213-226
48. The Gene Ontology Consortium. Gene ontology: tool for the unification of biology. Nat Genet 25 (2000) 25-29
49. Langmann T., Porsch-Ozcurumez M., Heimerl S., et al. Identification of sterol-independent regulatory elements in the human ATP-binding cassette transporter A1 promoter. Role of Sp1/3, E-box binding factors, and an oncostatin M-responsive element. J Biol Chem 277 (2002) 14443-14450
50. Li W.Q., Dehnade F., and Zafarullah M. Oncostatin M-induced matrix metalloproteinase and tissue inhibitor of metalloproteinase-3 genes expression in chondrocytes requires Janus kinase/STAT signaling pathway. J Immunol 166 (2001) 3491-3498
51. Ashkar S., Weber G.F., Panoutsakopoulou V., et al. Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science 287 (2000) 860-864
52. Warabi E., Wada Y., Kajiwara H., et al. Effect on endothelial cell gene expression of shear stress, oxygen concentration, and low-density lipoprotein as studied by a novel flow cell culture system. Free Radic Biol Med 37 (2004) 682-694
53. Healy A.M., Pickard M.D., Pradhan A.D., et al. Platelet expression profiling and clinical validation of myeloid-resistant protein-14 as a novel determinant of cardiovascular events. Circulation 113 (2006) 2278-2284
54. Tuomisto T.T., Korkeela A., Rutanen J., et al. Gene expression in macrophage-rich inflammatory cell infiltrates in human atherosclerotic lesions as studied by laser microdissection and DNA array: overexpression of HMG-CoA reductase, colony stimulating factor receptors, CD11A/CD18 integrins, and interleukin receptors. Arterioscler Thromb Vasc Biol 23 (2003) 2235-2240
55. Waehre T., Yndestad A., Smith C., et al. Increased expression of interleukin-1 in coronary artery disease with downregulatory effects of HMG-CoA reductase inhibitors. Circulation 109 (2004) 1966-1972
56. Montero I., Orbe J., Varo N., et al. C-reactive protein induces matrix metalloproteinase-1 and -10 in human endothelial cells: implications for clinical and subclinical atherosclerosis. J Am Coll Cardiol 47 (2006) 1369-1378
57. Blaschke F., Bruemmer D., Yin F., et al. C-reactive protein induces apoptosis in human coronary vascular smooth muscle cells. Circulation 110 (2004) 579-587
58. Geng Y.J., and Libby P. Progression of atheroma: a struggle between death and procreation. Arterioscler Thromb Vasc Biol 22 (2002) 1370-1380
59. Granger C.B., Van Eyk J.E., Mockrin S.C., Anderson N.L., and Working Group Members. National Heart, Lung, and Blood Institute Clinical Proteomics Working Group Report. Circulation 109 (2004) 1697-1703
60. Martin-Ventura J.L., Duran M.C., Blanco-Colio L.M., et al. Identification by a differential proteomic approach of heat shock protein 27 as a potential marker of atherosclerosis. Circulation 110 (2004) 2216-2219
61. Miller H., Poon S., Hibbert B., Rayner K., Chen Y.-X., and O'Brien E.R. Modulation of estrogen signaling by the novel interaction of heat shock protein 27, a biomarker for atherosclerosis, and estrogen receptor β: mechanistic insight into the vascular effects of estrogens. Arterioscler Thromb Vasc Biol 25 (2005) e10-e14
62. Duran M.C., Mas S., Martin-Ventura J.L., et al. Proteomic analysis of human vessels: application to atherosclerotic plaques. Proteomics 3 (2003) 973-978
63. Berhane B.T., Zong C., Liem D.A., et al. Cardiovascular-related proteins identified in human plasma by the HUPO Plasma Proteome Project pilot phase. Proteomics 5 (2005) 3520-3530
64. Ping P., Vondriska T.M., Creighton C.J., et al. A functional annotation of subproteomes in human plasma. Proteomics 5 (2005) 3506-3519
65. Karlsson H., Leanderson P., Tagesson C., and Lindahl M. Lipoproteomics I: mapping of proteins in low-density lipoprotein using two-dimensional gel electrophoresis and mass spectrometry. Proteomics 5 (2005) 551-565
66. Karlsson H., Leanderson P., Tagesson C., and Lindahl M. Lipoproteomics II: mapping of proteins in high-density lipoprotein using two-dimensional gel electrophoresis and mass spectrometry. Proteomics 5 (2005) 1431-1445
67. Davidsson P., Hulthe J., Fagerberg B., et al. A proteomic study of the apolipoproteins in LDL subclasses in patients with the metabolic syndrome and type 2 diabetes. J Lipid Res 46 (2005) 1999-2006
68. Brindle J.T., Antti H., Holmes E., et al. Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR-based metabonomics. Nat Med 8 (2002) 1439-1444
69. Sabatine M.S., Liu E., Morrow D.A., et al. Metabolomic identification of novel biomarkers of myocardial ischemia. Circulation 112 (2005) 3868-3875
70. Altshuler D., Brooks L.D., Chakravarti A., Collins F.S., Daly M.J., and Donnelly P. A haplotype map of the human genome. Nature 437 (2005) 1299-1320
71. Draghici S., Khatri P., Eklund A.C., and Szallasi Z. Reliability and reproducibility issues in DNA microarray measurements. Trends Genet 22 (2006) 101-109
72. Ehm M.G., Nelson M.R., and Spurr N.K. Guidelines for conducting and reporting whole genome/large-scale association studies. Hum Mol Genet 14 (2005) 2485-2488
73. Allison D.B., Cui X., Page G.P., and Sabripour M. Microarray data analysis: from disarray to consolidation and consensus. Nat Rev Genet 7 (2006) 55-65
74. Drews J. Drug discovery: a historical perspective. Science 287 (2000) 1960-1964
75. Hakonarson H., Thorvaldsson S., Helgadottir A., et al. Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trial. JAMA 293 (2005) 2245-2256